University of California San Francisco
Give to UCSF
UCSF Benioff Children’s Hospitals will pioneer stem cell transplants for a uniquely challenging patient population: second-trimester fetuses stricken with a potentially fatal disease.
Stephen L. Hauser will receive the 2017 Taubman Prize for Excellence in Translational Medical Research for his paradigm-changing discoveries that paved the way for a highly effective drug for the treatment of multiple sclerosis.
By piercing liver cells with rapid pulses of electricity, scientists at UC San Francisco have demonstrated an entirely new way to transplant cells into organs to treat disease.
A newly approved drug that is the first to reflect the current scientific understanding of multiple sclerosis is holding new hope for the hundreds of thousands Americans living with the disease. It also highlights the importance of clinician scientists like UCSF’s Stephen Hauser who are working to transform research into cures for patients.
In an unprecedented leap from lab to patients, a potential treatment for childhood epilepsy identified in experiments with zebrafish.
A novel gene therapy treatment may save infants from SCID, a devastating immune disorder commonly known as "bubble boy disease".
A $22 million investment via California State Assembly Bill 2664 is supporting innovation and entrepreneurship at UC San Francisco and across the University of California system.
UC San Francisco scientists have formed an innovative research alliance with three global pharmaceutical companies.
Children with severe cases of epilepsy such as Dravet syndrome are finding new and unexpected cures thanks to determined pediatricians and translational research at UCSF.
UCSF researchers have developed a new variety of targeting system for chemotherapy drugs based on the unusually high free iron content of many cancer cells.
The U.S. Food and Drug Administration has awarded the UCSF-Stanford Center of Excellence in Regulatory Science and Innovation (UCSF-Stanford CERSI) a five-year grant with up to $25 million in funding.
Researchers at UCSF and the academically affiliated Gladstone Institutes have used a newly developed gene-editing system to find gene mutations that make human immune cells resistant to HIV infection.
